A Study of Preeclampsia Recurrence
About This Grant
PROJECT SUMMARY/ABSTRACT Preeclampsia is a leading cause of maternal morbidity, maternal mortality, and iatrogenic preterm birth. Individuals at the highest risk for developing preeclampsia are those who had it in a prior pregnancy. However, not everyone recurs. Presentations of preeclampsia are heterogeneous, spanning from patients who spend weeks in the hospital prior to an extreme preterm birth to patients who are diagnosed incidentally during spontaneous, term labor. A major knowledge gap is understanding how variations in preeclampsia presentations relate to recurrence risk. This proposal outlines a research and training plan focused on studying drivers of preeclampsia recurrence with the goal of identifying strategies for mitigating risk. Aim 1 is to determine the relationship between subtypes of preeclampsia and risk of recurrence in a population representative of the United States. Aim 2 is to delineate the role of modifiable and non-modifiable risk factors in preeclampsia recurrence. This proposal leverages resources at Vanderbilt University Medical Center (VUMC) to achieve these aims. Clinical information and genetic data on over 12,900 patients receiving care at VUMC for two or more pregnancies are available for this analysis. Vanderbilt’s Precision Phenotyping Core will be utilized in the development and validation of algorithms for identifying preeclampsia subtypes in the electronic health record (EHR). Advanced quantitative methods will be used to determine risk of recurrence by preeclampsia subtypes, by heritability of disease quantified using a polygenic risk score, and by selected modifiable and non-modifiable risk factors including interpregnancy interval, interpregnancy weight gain, maternal smoking status, maternal age, and fetal sex. A major focus of this proposal is to support Dr. Sundermann’s career development. Her long-term career goal is to conduct epidemiologic and translational research that provides evidence around modifiable determinants of adverse pregnancy outcomes to identify targets for interventions as an independent physician-scientist in obstetrics and gynecology. She will accomplish this goal through training focused on gaining expertise in clinical informatics, reproductive epidemiology methods, and genetic analysis. The research environment for this proposal is excellent. Dr. Sundermann has full departmental and institutional support and access to VUMC’s shared resources for training and research. Her mentorship committee includes experts in obstetrics, genetic epidemiology, reproductive epidemiology, biomedical informatics, and biostatistics. This K01 will support work that delivers insight into the recurrence of one of the most common and morbid conditions of pregnancy while providing training that will serve as a vehicle for Dr. Sundermann’s transition to independence.
Grant Summary
A Study of Preeclampsia Recurrence is a NHLBI - National Heart Lung and Blood Institute grant providing up to $154K for university, nonprofit, healthcare org. Applications are due 2031-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $154K
2031-06-30
- 1Confirm your organization is eligible for A Study of Preeclampsia Recurrence from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
A Study of Preeclampsia Recurrence: Frequently Asked Questions
Who is eligible for the A Study of Preeclampsia Recurrence?
A Study of Preeclampsia Recurrence is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the A Study of Preeclampsia Recurrence provide?
A Study of Preeclampsia Recurrence provides up to $154K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the A Study of Preeclampsia Recurrence deadline?
Applications for A Study of Preeclampsia Recurrence are due 2031-06-30 (open). Because deadlines can change, verify the date with the funder, NHLBI - National Heart Lung and Blood Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the A Study of Preeclampsia Recurrence?
To apply for A Study of Preeclampsia Recurrence, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.